Disc Medicine, Inc. financial data

Symbol
IRON on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Arsenal Street, Suite 101, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Gemini Therapeutics, Inc. /DE (to 12/28/2022), FS Development Corp. (to 2/8/2021)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.09K % -0.83%
Debt-to-equity 5.34 % -6.49%
Return On Equity -25.2 % -12.2%
Return On Assets -24 % -12.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.8M shares +23.3%
Common Stock, Shares, Outstanding 29.7M shares +23.2%
Entity Public Float 508M USD +1651%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 29.9M shares +23.1%
Weighted Average Number of Shares Outstanding, Diluted 29.9M shares +23.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 94.4M USD +66.5%
General and Administrative Expense 30.4M USD +54.4%
Operating Income (Loss) -125M USD -63.4%
Nonoperating Income (Expense) 21.6M USD +74.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -103M USD -61.3%
Income Tax Expense (Benefit) 211K USD +470%
Net Income (Loss) Attributable to Parent -103M USD -61.4%
Earnings Per Share, Basic -3.91 USD/shares +60.7%
Earnings Per Share, Diluted -3.91 USD/shares +60.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 193M USD -48%
Marketable Securities, Current 295M USD
Cash, Cash Equivalents, and Short-term Investments 487M USD
Assets, Current 493M USD +31.8%
Property, Plant and Equipment, Net 79K USD -56.8%
Operating Lease, Right-of-Use Asset 1.68M USD -13.3%
Other Assets, Noncurrent 236K USD +103%
Assets 495M USD +31.5%
Accounts Payable, Current 3.55M USD -58.2%
Employee-related Liabilities, Current 4.57M USD +43.9%
Accrued Liabilities, Current 5.51M USD -0.99%
Liabilities, Current 25.5M USD +76.7%
Operating Lease, Liability, Noncurrent 1.71M USD +6.53%
Liabilities 27.2M USD +55.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 741K USD
Retained Earnings (Accumulated Deficit) -269M USD -62.7%
Stockholders' Equity Attributable to Parent 468M USD +30.4%
Liabilities and Equity 495M USD +31.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.6M USD +5.26%
Net Cash Provided by (Used in) Financing Activities 15.9M USD -79.4%
Net Cash Provided by (Used in) Investing Activities -67K USD -131%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 29.7M shares +23.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.8M USD -142%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 193M USD -48%
Interest Paid, Excluding Capitalized Interest, Operating Activities 47K USD -21.7%
Deferred Tax Assets, Valuation Allowance 61.8M USD +71.1%
Deferred Tax Assets, Gross 62.3M USD +70.6%
Operating Lease, Liability 2.1M USD +57.5%
Depreciation 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 67K USD +131%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.8M USD -82.7%
Lessee, Operating Lease, Liability, to be Paid 2.42M USD +63.2%
Operating Lease, Liability, Current 76K USD -78.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 850K USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year One 845K USD +127%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +90.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 323K USD +114%
Lessee, Operating Lease, Liability, to be Paid, Year Three 729K USD +85%
Deferred Tax Assets, Operating Loss Carryforwards 24.3M USD +28.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 336K USD
Additional Paid in Capital 736M USD +40.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26K USD +4%
Deferred Tax Assets, Net of Valuation Allowance 555K USD +32.1%
Share-based Payment Arrangement, Expense 14.4M USD +213%
Interest Expense 240K USD -96.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%